All the news

A peer-led recruitment strategy proved highly successful in engaging people who use drugs in testing and treatment for hepatitis C in the French city of Montpellier, researchers from the University of Montpellier report ...

People with hepatitis C remain at higher risk of chronic kidney disease after clearing or being cured of hepatitis C and people with genotype 1 infection have a higher risk of kidney ...

Greater efforts by healthcare providers to build trusting relationships with people with HIV and hepatitis C, together with a greater focus on overcoming concerns about treatment side effects, are likely to be needed ...

Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ...

The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ...

People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ...

Two combinations proved highly effective in curing hepatitis C in people who had experienced the failure of a previous combination containing an NS5A inhibitor, studies in Europe and New Zealand show. The findings, ...